This is the first post on the Astinova blog, and we want to start by mapping that territory. What follows is not a primer on degrader pharmacology. It is a field guide to the synthesis bench.<\/p>\n\n\n\n A representative CRBN-recruiting PROTAC. Aryl warhead (left), PEG3 linker (centre), lenalidomide-derived CRBN ligand (right). The whole molecule weighs in around 600 Da \u00e2\u20ac\u201d well past Lipinski territory.<\/p>\n\n\n\n The architecture, briefly<\/strong><\/p>\n\n\n\n A PROTAC is a heterobifunctional molecule with three parts:<\/p>\n\n\n\n The three canonical CRBN ligands. Thalidomide is the parent. Pomalidomide adds the aniline NH\u00e2\u201a\u201a \u00e2\u20ac\u201d the standard linker attachment site. Lenalidomide reduces one of the imide carbonyls, making the scaffold less electron-poor.<\/p>\n\n\n\n When both ends bind their respective proteins, the result is a ternary complex<\/strong>: POI\u00e2\u20ac\u201cPROTAC\u00e2\u20ac\u201cE3. Once ternary, the E3 tags the POI with ubiquitin, the proteasome degrades it, and the cycle repeats. The PROTAC itself is not consumed \u00e2\u20ac\u201d it is catalytic. That single property is the reason degraders can achieve durable target knockdown at concentrations far below those needed for occupancy-based inhibition.<\/p>\n\n\n\n That is the elegant version. The bench-level reality is messier.<\/p>\n\n\n\n Why PROTAC synthesis is genuinely hard<\/strong><\/p>\n\n\n\n Three features make PROTAC chemistry different in kind from conventional small-molecule medicinal chemistry.<\/p>\n\n\n\n 1. You are synthesizing past Lipinski<\/strong><\/p>\n\n\n\n Most PROTACs sit firmly outside Lipinski’s rule of five. Molecular weights above 800\u00e2\u20ac\u201c1000 Da, ten or more hydrogen-bond acceptors, and three or more hydrogen-bond donors are routine. This is not a defect of the chemistry. It is structural \u00e2\u20ac\u201d the molecule has to span two protein surfaces simultaneously.<\/p>\n\n\n\n The downstream consequences are unforgiving. Solubility is poor. Reverse-phase HPLC, the workhorse purification method, gets compromised because closely related linker analogs co-elute. Polar surface areas are large; passive permeability collapses. Crystallization for X-ray gets trickier as flexibility increases. None of these problems is individually fatal, but together they push the synthetic chemist into a different operating regime than a typical Lipinski-compliant kinase inhibitor program.<\/p>\n\n\n\n 2. The linker is half the molecule, and SAR on it is non-obvious<\/strong><\/p>\n\n\n\n The first generation of PROTAC linkers were PEG chains \u00e2\u20ac\u201d cheap, flexible, easy to install via amine couplings or click chemistry. Most of the early literature uses PEG2 through PEG6 linkers. They work. But PEG is a pharmacokinetic liability: it is metabolically labile, it contributes little to potency, and the resulting molecules tend to behave badly in vivo.<\/p>\n\n\n\n The field has moved decisively toward rigidified linkers<\/strong> \u00e2\u20ac\u201d piperazines, piperidines, spirocycles, bicyclic frameworks, occasionally macrocycles. These are harder to synthesize. They constrain the geometry of the ternary complex, which is good for selectivity but bad for synthesis tractability. Designing a “linker library” \u00e2\u20ac\u201d a series of compounds where only the linker varies \u00e2\u20ac\u201d usually means designing six or eight independent multi-step routes, not just swapping a single building block.<\/p>\n\n\n\n Four representative linker classes. Flexible PEGs and alkyl chains are easy to make and metabolically vulnerable. Rigid piperidine\u00e2\u20ac\u201cpiperazine and spirocyclic linkers preorganize the ternary complex but add multi-step synthetic burden.<\/p>\n\n\n\n And the SAR is genuinely strange. Adding two methylene units to a linker can move you from a productive degrader to a binder that does not degrade at all. Removing one carbon can rescue activity. The structure\u00e2\u20ac\u201cactivity relationship is governed by the geometry of the ternary complex, not by anything you can read off the PROTAC’s own structure. Linker SAR campaigns are empirical \u00e2\u20ac\u201d sometimes brutally so. They need to be planned as such from the start.<\/p>\n\n\n\n 3. The synthesis is long, and the protecting-group choreography matters<\/strong><\/p>\n\n\n\n A typical PROTAC published in the literature requires somewhere between 8 and 20 linear steps from commercial starting materials. The longest routes we have worked on have approached 25.<\/p>\n\n\n\n This is partly because all three pieces \u00e2\u20ac\u201d warhead, linker, E3 ligand \u00e2\u20ac\u201d usually need to be built separately and joined late. But it is also because each piece has its own protecting-group choreography. The CRBN ligands (lenalidomide, pomalidomide, thalidomide, and analogs) carry a glutarimide that is base-labile and a phthalimide nitrogen that competes with anything else nucleophilic on the molecule. VHL ligands carry a free hydroxyl that often needs masking until the final step. Warhead chemistry varies, but kinase ligands in particular often bring multiple unprotected anilines and heterocyclic N\u00e2\u20ac\u201cHs to the reaction.<\/p>\n\n\n\n Reactive sites on lenalidomide. The aniline NH\u00e2\u201a\u201a (blue) is the canonical linker attachment point. The glutarimide N\u00e2\u20ac\u201cH (amber) is base-labile and racemization-prone \u00e2\u20ac\u201d strong bases and prolonged exposure to amines will quietly destroy the scaffold.<\/p>\n\n\n\n The VHL recruiter has its own personality. The 4-hydroxyproline hydroxyl is the binding handle, but it is also nucleophilic enough to get in the way of any acyl-transfer chemistry you do downstream. The acetyl cap on the t-leucine end is stable but easy to lose under harsh basic hydrolysis. Most groups protect the hydroxyl as a silyl ether and unmask it only at the very end.<\/p>\n\n\n\n VH032 \u00e2\u20ac\u201d the canonical VHL ligand. The 4-hydroxyproline hydroxyl is the binding-critical handle. Most syntheses protect it as a silyl ether until the final deprotection step.<\/p>\n\n\n\n Get the order of operations wrong, and you are back at step four with a yellow flask and a lesson learned.<\/p>\n\n\n\n What this means for outsourced chemistry<\/strong><\/p>\n\n\n\n We see two patterns when biotech teams bring PROTAC programs to a CRO that was not built for them.<\/p>\n\n\n\n The first is route timing<\/strong>. PROTACs reward late-stage diversification \u00e2\u20ac\u201d that is, building the warhead and E3 ligand separately, then varying the linker and the coupling chemistry to generate a focused matrix of analogs. Most discovery CROs are organized around linear, single-target syntheses; they are not set up to deliver a matched series of twenty analogs that differ only in their linker. The result is either delays or compromises in the SAR.<\/p>\n\n\n\n The second is analytical depth<\/strong>. The structural similarity between PROTAC analogs makes purity assessment genuinely demanding. A 95% pure PROTAC with the wrong linker isomer at 4% can mislead an entire SAR table. We have seen ambiguous bioassay results that traced back, eventually, to inadequate chromatographic separation between a target compound and its des-methylene impurity. PROTAC programs need analytical chemistry that is better than the conventional 95% HPLC purity standard \u00e2\u20ac\u201d orthogonal HPLC methods, NMR-confirmed regiochemistry, and ideally HRMS confirmation of each linker analog.<\/p>\n\n\n\n These are not exotic capabilities. They are simply expensive to do casually, and easy to skip when the deadline is short.<\/p>\n\n\n\n The bigger picture<\/strong><\/p>\n\n\n\n The most interesting frontier in PROTAC chemistry over the next two or three years will probably not be on the warhead side. Warhead chemistry has been mature for a long time, and most targeted-protein-degradation programs reuse known inhibitor scaffolds. The frontier is in the linker and in the E3 ligand.<\/p>\n\n\n\n On the linker side: bicyclic and macrocyclic constrained scaffolds that pre-organize the ternary complex geometry, replacing flexible PEGs with conformationally locked frameworks. The synthesis of these scaffolds is harder, but the medicinal chemistry payoff \u00e2\u20ac\u201d better cellular permeability, cleaner metabolism, more predictable PK \u00e2\u20ac\u201d is real and increasingly demonstrated.<\/p>\n\n\n\n On the E3 ligand side: the field is finally pushing beyond CRBN and VHL. CRBN-based PROTACs work in many contexts but suffer from a well-documented resistance liability \u00e2\u20ac\u201d the same mutations that desensitize IMiDs in multiple myeloma desensitize CRBN-recruiting degraders. VHL-based PROTACs avoid that, but have their own pharmacology and tissue-distribution constraints. The next wave \u00e2\u20ac\u201d KEAP1, DCAF15, DCAF1, FEM1B, RNF114 \u00e2\u20ac\u201d opens up tissue-specific degradation and new biology, but every new E3 ligand brings a new ligand series that has to be developed and characterized as carefully as the rest of the molecule.<\/p>\n\n\n\n Both of these are chemistry problems. Both are tractable. Neither will be solved by biology teams alone.<\/p>\n\n\n\n What we’ll write about next<\/strong><\/p>\n\n\n\n This is the first post. We expect the rest of the Astinova blog to be a mix of:<\/p>\n\n\n\n If there is a specific topic you would like us to cover \u00e2\u20ac\u201d PROTAC linker design, ADC bioconjugation chemistry, asymmetric synthesis on scale, anything else in the advanced modality space \u00e2\u20ac\u201d write to us at info@astinovabiolabs.com<\/a>.<\/p>\n\n\n\n Welcome to the Astinova blog.<\/p>\n","protected":false},"excerpt":{"rendered":" In the last five years, targeted protein degradation has gone from an academic curiosity to an industry-wide drug discovery priority. Roughly thirty PROTACs are in human clinical trials as of early 2026. Several are deep into Phase 2…<\/p>\n","protected":false},"author":1,"featured_media":16,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,2],"tags":[5,3,4,6,7],"class_list":["post-15","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog","category-protacs","tag-crbn","tag-medicinal-chemistry","tag-protac","tag-targeted-protein-degradation","tag-vhl"],"_links":{"self":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/15","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/comments?post=15"}],"version-history":[{"count":1,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/15\/revisions"}],"predecessor-version":[{"id":17,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/15\/revisions\/17"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/media\/16"}],"wp:attachment":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/media?parent=15"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/categories?post=15"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/tags?post=15"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"\"](\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/05\/01-protac-dbet1-1024x444.png\")
<\/figure>\n\n\n\n\n
![\"\"](\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/05\/02-crbn-ligands-1024x289.png\")
<\/figure>\n\n\n\n![\"\"](\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/05\/04-linker-types-1024x709.png\")
<\/figure>\n<\/figure>\n\n\n\n![\"\"](\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/05\/05-lenalidomide-reactivity-1024x512.png\")
<\/figure>\n\n\n\n![\"\"](\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/05\/03-vhl-ligand-1024x473.png\")
<\/figure>\n\n\n\n\n